Alector Inc.
12
1
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
33.3%
4 terminated/withdrawn out of 12 trials
60.0%
-26.5% vs industry average
17%
2 trials in Phase 3/4
67%
4 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
Role: lead
Open-label Extension Study in Participants With Early Alzheimer's Disease
Role: collaborator
Continuation Study for Latozinemab
Role: lead
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Role: lead
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Role: lead
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
Role: collaborator
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Role: lead
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
Role: lead
A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101
Role: lead
First in Human Study for Safety and Tolerability of AL003.
Role: lead
A Phase I Study for Safety and Tolerability of AL002.
Role: lead
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
Role: lead
All 12 trials loaded